INKT

Mink Therapeutics, Inc.

• Reuters·1d ago

  Mink Therapeutics files Form 3 for Principal Financial Officer Melissa Orilall

• Reuters·04/03 11:30

  Mink Therapeutics, MSKCC to present Phase II agenT-797 combo study in refractory GEC at AACR

• Reuters·04/03 11:30

  Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR

• Reuters·04/02 11:34

  Mink Therapeutics to present new agenT-797 data at ASGCT meeting

• Benzinga·04/02 11:32

  MiNK Therapeutics To Present New Data At ASGCT 2026 Showing iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS

• Reuters·04/02 11:30

  MiNK Therapeutics’ agenT-797 iNKT cell therapy data accepted for ASGCT 2026 presentation

• Dow Jones·04/01 11:35

  MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

• Reuters·04/01 11:31

  Mink Therapeutics to present agenT-797 combination therapy abstract at ATS conference

• Benzinga·04/01 11:25

  HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

• TipRanks·04/01 10:15

  MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst

• TipRanks·04/01 00:25

  MiNK Therapeutics’ Earnings Call Signals High-Risk Upside

• Seeking Alpha·03/31 15:03

  MiNK outlines initial ARDS Phase II data in H2 2026 while extending runway through 2026

• Seeking Alpha·03/31 11:34

  MiNK Therapeutics GAAP EPS of -$0.56 beats by $0.12

• Benzinga·03/31 11:32

  MiNK Therapeutics Reports Progress in New Treatments for Lung Disease, Cancer and Immune Disorders

• Dow Jones·03/31 11:31

  *MiNK Therapeutics 4Q Loss/Shr 56c >INKT